

SKYEPHARMA PLC
Form 6-K
November 20, 2006

**SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of November, 2006

SkyePharma PLC

(Translation of registrant's name into English)

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

Edgar Filing: SKYEPHARMA PLC - Form 6-K

SkyePharma PLC

SKYEPHARMA TO PRESENT AT 18th ANNUAL PIPER JAFFRAY

HEALTH CARE CONFERENCE

LONDON, UK, 20 November 2006 -- SkyePharma PLC (Nasdaq: SKYE; LSE: SKP) announces today that the Company's Chief Executive Officer, Frank Condella, will make a presentation at the 18th Annual Piper Jaffray Health Care Conference at the Pierre Hotel, New York. Mr. Condella will deliver his presentation on Thursday, November 30, 2006 at 3.30 p.m. ET (8.30 p.m. GMT). Investors may access a live webcast of the presentation at www.skyepharma.com under the Investor Relations tab. The presentation will be archived for 30 days.

For further information please contact:

SkyePharma PLC

Frank Condella, Chief Executive Officer
Ken Cunningham, Chief Operating Officer

+44 207 491 1777

Buchanan Communications

Tim Anderson / Mark Court / Rebecca Skye Dietrich

+44 207 466 5000

The Trout Group

Seth Lewis

+ 1 617 583 1308

About SkyePharma PLC

SkyePharma PLC develops pharmaceutical products benefiting from world-leading drug delivery technologies that provide easier-to-use and more effective drug formulations. There are now eleven approved products incorporating SkyePharma's technologies in the areas of oral, injectable, inhaled and topical delivery, supported by advanced solubilisation capabilities. For more information, visit www.skyepharma.com.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SkyePharma PLC

By: /s/ Douglas Parkhill

Edgar Filing: SKYEPHARMA PLC - Form 6-K

Name: Douglas Parkhill
Title: Company Secretary

Date: November 20, 2006